Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems

详细信息    查看全文

• 作者：Hae Ryung Chang ; Hee Seo Park ; Young Zoo Ahn ; Seungyoon Nam ; Hae Rim Jung…
• 关键词：Biomarker ; Cell microarray ; ERBB2 expression ; Gastric cancer cell lines ; Targeted therapies ; Trastuzumab ; Tumor heterogeneity ; Xenograft microarray
• 刊名：BMC Cancer
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：3,330 KB
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background “Biomarker-driven targeted therapy,” the practice of tailoring patients’ treatment to the expression/activity levels of disease-specific genes/proteins, remains challenging. For example, while the anti-ERBB2 monoclonal antibody, trastuzumab, was first developed using well-characterized, diverse in vitro breast cancer models (and is now a standard adjuvant therapy for ERBB2-positive breast cancer patients), trastuzumab approval for ERBB2-positive gastric cancer was largely based on preclinical studies of a single cell line, NCI-N87. Ensuing clinical trials revealed only modest patient efficacy, and many ERBB2-positive gastric cancer (GC) patients failed to respond at all (i.e., were inherently recalcitrant), or succumbed to acquired resistance.